The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study

Respiration; International Review of Thoracic Diseases
Yoshihiro Kobashi, Toshiharu Matsushima

Abstract

The difficulty of treatment for pulmonary Mycobacterium avium complex (MAC) in Japan. To investigate the clinical and microbiological effects of treatment according to the guidelines proposed by the American Thoracic Society and the Japanese Society for Tuberculosis and prospective follow-up studies after the completion of treatment of patients with pulmonary MAC disease. Analysis of the microbiological effects with regard to sputum conversion rate and the sputum relapsing rate and the clinical effects with regard to clinical symptoms and radiological findings for patients with pulmonary MAC disease treated with a regimen consisting of rifampicin, ethambutol, streptomycin, and clarithromycin over 24 months and follow-up over 12 months. Sixty-five patients with pulmonary MAC disease were enrolled in this trial. In 39 patients, negative sputum conversion was observed within 6 months after the initiation of this regimen, 16 relapsed, and 20 experienced clinical worsening within 1 year after the completion of treatment. Although retreatment with the same regimen or a regimen including new quinolones was carried out for these patients, we could not achieve negative sputum conversion and/or clinical improvement. We believe that the d...Continue Reading

References

Dec 1, 1986·Journal of Clinical Microbiology·R J WallaceV Steingrube
Nov 1, 1993·Antimicrobial Agents and Chemotherapy·L HeifetsJ Vanderkolk
Mar 1, 1993·Diagnostic Microbiology and Infectious Disease·R J WallaceD E Griffith
Jun 1, 1996·American Journal of Respiratory and Critical Care Medicine·R J WallaceD T Murphy
Apr 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C M Kunin
Jul 1, 1997·American Journal of Respiratory and Critical Care Medicine·R P Baughman
Sep 3, 1999·American Journal of Respiratory and Critical Care Medicine·E TanakaF Kuze

❮ Previous
Next ❯

Citations

Jul 27, 2010·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Meng-Chuan ShenYung-Ching Liu
Feb 1, 2013·QJM : Monthly Journal of the Association of Physicians·C Zheng, C H Fanta
Apr 23, 2008·Current Opinion in Pulmonary Medicine·Margaret M JohnsonJack P Leventhal
Mar 24, 2009·Current Opinion in Pulmonary Medicine·Sandra M ArendTom H M Ottenhoff
Aug 11, 2012·American Journal of Respiratory and Critical Care Medicine·Won-Jung KohSung Jae Shin
Jul 3, 2013·Internal Medicine·Yoshihiro KobashiMikio Oka
Mar 12, 2011·Emerging Infectious Diseases·Sami SimonsDick van Soolingen
Nov 12, 2013·Emerging Infectious Diseases·Theodore K MarrasFrances B Jamieson
Nov 19, 2013·Annals of the American Thoracic Society·Jennifer AdjemianDavid Griffith
Oct 3, 2013·Annals of the American Thoracic Society·Theodore K MarrasUNKNOWN Pulmonary MAC Outcomes Group
Jan 3, 2016·The Journal of Infection·S CowmanM R Loebinger
Mar 26, 2011·The Korean Journal of Internal Medicine·Eun Young KimYong Soo Kwon
Sep 30, 2010·Yonsei Medical Journal·Yun Su SimWon-Jung Koh
Jun 28, 2008·Journal of Korean Medical Science·Won-Jung KohJhingook Kim
Aug 27, 2014·FEMS Microbiology Letters·Eun KimEdward D Chan
Mar 14, 2014·Asian Cardiovascular & Thoracic Annals·Katsunari MatsuokaYoshihiro Miyamoto
Dec 19, 2016·F1000Research·David E Griffith, Timothy R Aksamit
Dec 7, 2018·Breathe·Mimi LuBen J Marais
May 7, 2020·Journal of Clinical Medicine·Kiyoharu FukushimaHiroshi Kida
Nov 29, 2011·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Asuka MinematsuShigeru Kohno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.